Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

Share Price is delayed by 15 minutes
Get Live Data
88.50    1.00 (1.14%)
Bid:
87.00
Ask:
90.00
Spread: 3.00 (3.448%)
Market Cap: £59.37m
EAH Live PriceLast checked at - London Stock Exchange

Intraday Eco Animal Share Chart

Share Awards to Executive Directors

22 Mar 2024 07:00

RNS Number : 8755H
Eco Animal Health Group PLC
22 March 2024
 

22 March 2024

 

  

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Share Awards to Executive Directors

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announced that on 21 March 2024, nominal cost conditional share options were granted under the Company's Long Term Incentive Plan (the "LTIP") over 176,652 ordinary shares in the Company (representing approximately 0.26 percent of the Company's issued share capital) to Executive Directors listed below.

 

Name

Position

Number of Share Awards

David Hallas

Chief Executive Officer

101,403

Chris Wilks

Chief Financial Officer

75,249

 

These awards under the LTIP are subject to performance conditions being met which have been set by the Company's Remuneration Committee and relate to Total Shareholder Return ("TSR") and Research and Development ("R&D") targets. Subject to the performance conditions being met, awards will vest after the end of a three year vesting period. Further details on the LTIP can be found in the Company's 2022 Annual Report.

-Ends-

For further information please contact:

 

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)

020 8447 8899

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

Sam Butcher

020 7496 3000

Investec (Joint Broker)

Gary Clarence

Lydia Zychowska

020 7597 5970

 

 

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

ICR Consilium (Financial PR)

Mary-Jane Elliott

Jessica Hodgson

020 3709 5700

ecoanimalhealth@consilium-comms.com

 

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

 

PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

David Hallas

 

2.

Reason for the notification

a.

Position/status

Chief Executive Officer

 

b.

Initial notification

/Amendment

 

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Eco Animal Health Group Plc

b.

LEI

2138009XN9DJ3YP70B55

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Options over ordinary shares of 5p each.

 

GB0032036807 

 

b.

Nature of the transaction

Award of nominal cost conditional share awards under the Company's LTIP.

c.

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

5p

101,403

d.

Aggregated information

Aggregated volume

Price 

 

 

n/a

 

e.

Date of the transaction

21 March 2024

f.

Place of the transaction

Outside a trading venue.

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Chris Wilks

 

2.

Reason for the notification

a.

Position/status

Chief Financial Officer

 

b.

Initial notification

/Amendment

 

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Eco Animal Health Group Plc

b.

LEI

2138009XN9DJ3YP70B55

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Options over ordinary shares of 5p each.

 

GB0032036807 

 

b.

Nature of the transaction

Award of nominal cost conditional share awards under the Company's LTIP.

c.

Price(s) and volume(s)

 

 

Price(s)

 

Volume(s)

5p

75,249

d.

Aggregated information

Aggregated volume

Price 

 

 

n/a

 

e.

Date of the transaction

21 March 2024

f.

Place of the transaction

Outside a trading venue.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFFLLLZXLFBBE
Date   Source Headline
4th Jun 20267:00 amRNSRenewal of revolving credit facility
14th Apr 20267:00 amRNSAppointment of Head of Business Development
31st Mar 20267:00 amRNSBoard Change
19th Mar 20267:00 amRNSFull Year Trading Update
11th Mar 20267:00 amRNSECOVAXXIN® MG favourable USDA safety assessment
11th Mar 20267:00 amRNSECOVAXXIN®?MG favourable USDA safety assessment
5th Mar 20264:19 pmRNSBlock Listing Return
26th Feb 20267:00 amRNSEU launch plans for ECOVAXXIN® MS
19th Jan 20261:50 pmRNSHolding(s) in Company
22nd Dec 20257:00 amRNSECOVAXXIN® MS EU marketing authorisation granted
22nd Dec 20257:00 amRNSECOVAXXIN® MS EU marketing authorisation granted
18th Dec 20257:00 amRNSExercise of Share Options by Director
9th Dec 20255:57 pmRNSHolding(s) in Company
4th Dec 20252:10 pmRNSDirector/PDMR Shareholding
1st Dec 20257:00 amRNSResults for the six months ended 30 September 2025
20th Nov 20259:47 amRNSReplacement: Notice of Results
20th Nov 20257:00 amRNSNotice of Results
10th Nov 20257:00 amRNSEMA Positive Opinion Received for ECOVAXXIN® MS
1st Oct 20257:00 amRNS-RHead of Global R&D
25th Sep 20253:15 pmRNSResult of AGM
25th Sep 20257:00 amRNSAGM Trading Update and Notice of Interim Results
1st Sep 20257:00 amRNSAppointment of Joint Broker
29th Aug 20257:00 amRNSShare Awards to Executive Directors
28th Aug 20257:48 amRNSPosting of Annual Report and Notice of AGM
21st Aug 202512:29 pmRNSResult of General Meeting
13th Aug 20257:00 amRNSBlock Listing Return
6th Aug 20255:09 pmRNSHolding(s) in Company
17th Jul 20257:00 amRNSHolding(s) in Company
15th Jul 20251:00 pmRNSDirector/PDMR Shareholding
14th Jul 20257:00 amRNSResults for the year ended 31 March 2025
8th Jul 20254:10 pmRNSNotice of General Meeting and Notice of Results
2nd May 20257:00 amRNSHolding(s) in Company
28th Apr 20257:00 amRNSDirector/PDMR Shareholding
24th Apr 20257:00 amRNSTrading Update
13th Mar 20257:00 amRNSR&D Day
3rd Mar 20257:00 amRNSSubmission of Marketing Authorisation Application
24th Feb 20254:08 pmRNSHolding(s) in Company
19th Feb 20257:00 amRNSDisposal of non-core assets
18th Feb 20257:00 amRNSBlock listing Interim Review
13th Feb 20257:00 amRNSNotice of R&D Day
31st Jan 20257:00 amRNSBoard Changes
20th Dec 20247:00 amRNSHolding(s) in Company
16th Dec 20247:00 amRNSHolding(s) in Company
2nd Dec 202412:30 pmRNSShare Purchase by Executive Director
28th Nov 20247:00 amRNSResults for the Six Months Ended 30 September 2024
28th Oct 202412:57 pmRNSShare Awards to Executive Directors
22nd Oct 202411:00 amRNSEBT Share Purchase
21st Oct 20247:00 amRNSEBT Share Purchase
14th Oct 202411:07 amRNSEBT Share Purchase
9th Oct 20247:00 amRNSIssue of Equity and TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.